Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Germany debates breast cancer screening programme:

This article was originally published in Clinica

Executive Summary

A forum established to co-ordinate a European programme to fight breast cancer last week concentrated on how a screening programme could speedily be introduced to Germany. By the end of 2003, experts hope to have introduced across the country a quality-assured screening programme based on European guidelines. Results from a number of German projects, started six months ago, were presented at the forum. Dr Margrit Reichel, who ran one of the projects in Wiesbaden, said that some 3,400 women had taken part, roughly half of those who had been invited. "The women screened were between the ages of 50-69," she told Clinica. 50 breast cancers have so far been detected, she said, a higher number than expected. This had made the projects a genuine success.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT064582

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel